David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Ezio Di Nucci
Jack Alan Reynolds
Learn more about PhilPapers
American Journal of Bioethics 6 (5):W1-W5 (2006)
This article endeavors to place into context recent developments surrounding the United States Food and Drug Administration recent approval of BiDil? (isosorbide dinitrate/hydralazine hydrochloride) (NitroMed, Inc., Lexington, MA) as the first ever race-specific drug?in this case to treat heart failure in African Americans. It focuses in particular on both commercial incentives and statistical manipulation of medical data as framing the drive to bring BiDil to market as a race-specific drug. In current discourse about pharmacogenomics, targeting a racial audience is perceived as necessary because at this point the technology and resources do not exist to scan efficiently every individual's genetic profile. The article argues that medical researchers may say they are using race as a surrogate to target biology in drug development, but corporations are using biology as a surrogate to target race in drug marketing. Pharmacogenomics may hold great promise, but on our way to that Promised Land, it is imperative to review such short cuts with a critical eye
|Keywords||No keywords specified (fix it)|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library|
References found in this work BETA
Jonathan Kahn (2003). Getting the Numbers Right: Statistical Mischief and Racial Profiling in Heart Failure Research. Perspectives in Biology and Medicine 46 (4):473-483.
Citations of this work BETA
No citations found.
Similar books and articles
Britt M. Rusert & Charmaine D. M. Royal (2011). Grassroots Marketing in a Global Era: More Lessons From BiDil. Journal of Law, Medicine & Ethics 39 (1):79-90.
Jonathan Kahn (2012). The Troubling Persistence of Race in Pharmacogenomics. Journal of Law, Medicine & Ethics 40 (4):873-885.
Susan M. Reverby (2008). “Special Treatment”: BiDil, Tuskegee, and the Logic of Race. Journal of Law, Medicine & Ethics 36 (3):478-484.
Timothy Caulfield & Simrat Harry (2008). Popular Representations of Race: The News Coverage of BiDil. Journal of Law, Medicine & Ethics 36 (3):485-490.
Joon-ho Yu, Sara Goering & Stephanie M. Fullerton (2009). Race-Based Medicine and Justice as Recognition: Exploring the Phenomenon of BiDil. Cambridge Quarterly of Healthcare Ethics 18 (1):57.
Karen Peterson-Iyer (2008). Pharmacogenomics, Ethics, and Public Policy. Kennedy Institute of Ethics Journal 18 (1):pp. 35-56.
Homer B. Warren, David J. Burns & James Tackett (2012). The Likelihood of Deception in Marketing. Business and Professional Ethics Journal 31 (1):109-134.
Janet Borgerson & Jonathan Schroeder (2002). Ethical Issues of Global Marketing: Avoiding Bad Faith in Visual Representation. European Journal of Marketing 36 (5/6):570-594.
Richard Tutton, Andrew Smart, Paul A. Martin, Richard Ashcroft & George T. H. Ellison (2008). Genotyping the Future: Scientists' Expectations About Race/ Ethnicity After BiDil. Journal of Law, Medicine & Ethics 36 (3):464-470.
George G. Brenkert (2008). Marketing Ethics. Blackwell Pub..
Luís Aráujo, John Finch & Hans Kjellberg (eds.) (2010). Reconnecting Marketing to Markets. Oxford University Press.
Donald P. Robin (1991). Epistemological Structures in Marketing. Business Ethics Quarterly 1 (2):185-200.
Patrick E. Murphy (1999). Character and Virtue Ethics in International Marketing: An Agenda for Managers, Researchers and Educators. [REVIEW] Journal of Business Ethics 18 (1):107 - 124.
Added to index2010-09-14
Total downloads8 ( #381,178 of 1,792,816 )
Recent downloads (6 months)1 ( #464,764 of 1,792,816 )
How can I increase my downloads?